Atea Pharmaceuticals, Inc.
AVIR
$3.96
$0.133.39%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 16.82M | 18.06M | 16.14M | 28.95M | 14.72M |
| Gross Profit | -16.82M | -18.06M | -16.14M | -28.95M | -14.72M |
| SG&A Expenses | 11.53M | 12.60M | 13.17M | 12.62M | 12.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.35M | 30.66M | 29.31M | 41.57M | 27.08M |
| Operating Income | -28.35M | -30.66M | -29.31M | -41.57M | -27.08M |
| Income Before Tax | -38.82M | -32.92M | -27.93M | -35.27M | -34.31M |
| Income Tax Expenses | 349.00K | 221.00K | 251.00K | 197.00K | 123.00K |
| Earnings from Continuing Operations | -39.16M | -33.14M | -28.18M | -35.47M | -34.43M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.16M | -33.14M | -28.18M | -35.47M | -34.43M |
| EBIT | -28.35M | -30.66M | -29.31M | -41.57M | -27.08M |
| EBITDA | -28.25M | -30.56M | -29.20M | -41.47M | -26.97M |
| EPS Basic | -0.47 | -0.40 | -0.34 | -0.43 | -0.41 |
| Normalized Basic EPS | -0.15 | -0.17 | -0.16 | -0.26 | -0.16 |
| EPS Diluted | -0.47 | -0.40 | -0.34 | -0.43 | -0.41 |
| Normalized Diluted EPS | -0.15 | -0.17 | -0.16 | -0.26 | -0.16 |
| Average Basic Shares Outstanding | 83.44M | 83.40M | 83.40M | 83.33M | 83.29M |
| Average Diluted Shares Outstanding | 83.44M | 83.40M | 83.40M | 83.33M | 83.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
